格列本脲对临床相关小鼠创伤性脑损伤MRI内表型的精准效应
本研究为盲法随机对照临床前试验,在成年雄性C57BL/6J小鼠(n=54)中比较格列本脲对两种重型TBI模型(单纯控制性皮质撞击CCI、CCI+失血性休克HS)MRI内表型的影响。小鼠随机接受溶媒、低剂量(20 μg/kg)或高剂量格列本脲(10 μg/鼠),并持续7天皮下输注(0.4 μg/hr)。结果显示CCI与CCI+HS产生的MRI水肿内表型存在显著异质性(均p<0.05);高剂量格列本脲使CCI后血肿体积减少约60%(p=0.0001)、CCI+HS后减少约48%(p=4.1×10-6),抗水肿获益主要见于CCI,低剂量无获益。作者认为这些发现有助于解读正在进行的试验及未来TBI试验的精准设计。
要点
- 高剂量格列本脲(10 μg/鼠,7天皮下输注0.4 μg/hr)使CCI后血肿体积减少约60%(p=0.0001),CCI+HS后减少约48%(p=4.1×10-6)。
- 抗水肿获益主要见于单纯CCI:高剂量格列本脲使同侧皮质多个MRI内表型正常化(血肿体积、T2、ADC、T1增强后均p<0.05)。
- 急性效应(3小时)特异于血肿(p=0.001)和细胞毒性水肿减少(p=0.0045);血管源性水肿可能需要更长治疗窗。
- 低剂量格列本脲(20 μg/kg)无获益;CCI与CCI+HS产生的MRI水肿内表型存在显著异质性(均p<0.05)。
- 作者认为这些发现可为正在进行的试验解读及未来TBI试验的精准设计(剂量、样本量估计、患者选择、结局选择、贝叶斯分析)提供新见解。
适用人群与场景
- 成年雄性C57BL/6J小鼠(n=54),用于两种确立的重型TBI模型:控制性皮质撞击(CCI,孤立脑挫伤)和CCI+失血性休克(HS,临床常见的二次打击)。
- 临床前实验室场景。
处置流程与药物剂量
- 小鼠随机分为 naïve、CCI±HS 联合溶媒、低剂量格列本脲(20 μg/kg)或高剂量格列本脲(10 μg/鼠)组。
- 格列本脲以7天皮下输注方式给药,输注速率0.4 μg/hr。
研究设计与关键结果
- 设计:盲法随机对照临床前试验,在两种重型TBI模型(CCI和CCI+HS)中评估格列本脲对MRI内表型的影响,样本为成年雄性C57BL/6J小鼠 n=54。
- 干预与对照:小鼠随机接受溶媒、低剂量格列本脲(20 μg/kg)或高剂量格列本脲(10 μg/鼠),7天皮下输注(0.4 μg/hr);另设naïve组。
- 主要终点:系列MRI(3小时、6小时、24小时和7天)测量血肿和水肿体积、T2弛豫(血管源性水肿)、表观扩散系数(ADC,细胞/细胞毒性水肿)及7天T1增强后值(血脑屏障完整性)。
- 异质性:CCI与CCI+HS产生的MRI水肿内表型存在显著异质性(均p<0.05)。
- 血肿体积:高剂量格列本脲使CCI后血肿体积减少约60%(p=0.0001),使CCI+HS后减少约48%(p=4.1×10-6),均与溶媒比较。
- 抗水肿获益:主要见于CCI,高剂量格列本脲使同侧皮质多个MRI内表型正常化(血肿体积、T2、ADC、T1增强后均p<0.05)。
- 急性效应:3小时效应特异于血肿(p=0.001)和细胞毒性水肿减少(p=0.0045)。
- 其他:高剂量格列本脲在TBI合并HS后减少血肿体积,但抗水肿效应不稳健;低剂量格列本脲无获益。
证据类型、等级与局限
- 证据类型:盲法随机对照临床前试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,高剂量格列本脲在孤立脑挫伤后对血肿体积、血管源性水肿、细胞毒性水肿和血脑屏障完整性有益;血肿和细胞毒性水肿效应是急性的,血管源性水肿可能允许更长治疗窗。
- 作者认为,这些发现为正在进行的试验解读以及未来TBI试验的精准设计(剂量、样本量估计、患者选择、结局选择、贝叶斯分析)提供新见解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Addressing traumatic brain injury (TBI) heterogeneity is increasingly recognized as essential for therapy translation given the long history of failed clinical trials. We evaluated differential effects of a promising treatment (glibenclamide) based on dose, TBI type (patient selection), and imaging endophenotype (outcome selection). Our goal to inform TBI precision medicine is contextually timely given ongoing phase 2/planned phase 3 trials of glibenclamide in brain contusion.
DESIGN: Blinded randomized controlled preclinical trial of glibenclamide on MRI endophenotypes in two established severe TBI models: controlled cortical impact (CCI, isolated brain contusion) and CCI+hemorrhagic shock (HS, clinically common second insult).
SETTING: Preclinical laboratory.
SUBJECTS: Adult male C57BL/6J mice (n = 54).
INTERVENTIONS: Mice were randomized to naïve, CCI±HS with vehicle/low-dose (20 μg/kg)/high-dose glibenclamide (10 μg/mouse). Seven-day subcutaneous infusions (0.4 μg/hr) were continued.
MEASUREMENTS AND MAIN RESULTS: Serial MRI (3 hr, 6 hr, 24 hr, and 7 d) measured hematoma and edema volumes, T2 relaxation (vasogenic edema), apparent diffusion coefficient (ADC, cellular/cytotoxic edema), and 7-day T1-post gadolinium values (blood-brain-barrier [BBB] integrity). Linear mixed models assessed temporal changes. Marked heterogeneity was observed between CCI versus CCI+HS in terms of different MRI edema endophenotypes generated (all p < 0.05). Glibenclamide had variable impact. High-dose glibenclamide reduced hematoma volume ~60% after CCI (p = 0.0001) and ~48% after CCI+HS (p = 4.1 × 10-6) versus vehicle. Antiedema benefits were primarily in CCI: high-dose glibenclamide normalized several MRI endophenotypes in ipsilateral cortex (all p < 0.05, hematoma volume, T2, ADC, and T1-post contrast). Acute effects (3 hr) were specific to hematoma (p = 0.001) and cytotoxic edema reduction (p = 0.0045). High-dose glibenclamide reduced hematoma volume after TBI with concomitant HS, but antiedema effects were not robust. Low-dose glibenclamide was not beneficial.
CONCLUSIONS: High-dose glibenclamide benefitted hematoma volume, vasogenic edema, cytotoxic edema, and BBB integrity after isolated brain contusion. Hematoma and cytotoxic edema effects were acute; longer treatment windows may be possible for vasogenic edema. Our findings provide new insights to inform interpretation of ongoing trials as well as precision design (dose, sample size estimation, patient selection, outcome selection, and Bayesian analysis) of future TBI trials of glibenclamide.
参考来源
- Zusman BE, Wu Y, Kochanek PM, et al. Precision Effects of Glibenclamide on MRI Endophenotypes in Clinically Relevant Murine Traumatic Brain Injury. Crit Care Med. 2022. PMID: 36661464. doi:10.1097/CCM.0000000000005749
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。